Get the Stockscreener App
1.105
3.27%
0.035
Alector Inc stock is traded at $1.105, with a volume of 1.33M.
It is up +3.27% in the last 24 hours and up +2.31% over the past month.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
See More
Previous Close:
$1.07
Open:
$1.07
24h Volume:
1.33M
Relative Volume:
1.64
Market Cap:
$110.49M
Revenue:
$100.56M
Net Income/Loss:
$-119.05M
P/E Ratio:
-0.8984
EPS:
-1.23
Net Cash Flow:
$-231.16M
1W Performance:
+6.25%
1M Performance:
+2.31%
6M Performance:
-72.82%
1Y Performance:
-80.44%
1-Day Range:
$1.01
$1.11
1-Week Range:
$1.01
$1.259
52-Week Range:
$0.87
$6.78
Alector Inc Stock (ALEC) Company Profile
Name
Alector Inc
Sector
Industry
Phone
415-231-5660
Address
131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO
Compare ALEC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALEC
Alector Inc
|
1.105 | 103.99M | 100.56M | -119.05M | -231.16M | -1.23 |
|
ONC
Beigene Ltd Adr
|
225.77 | 25.49B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.38 | 110.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.32 | 38.69M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
584.99 | 59.13B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
69.53 | 5.64B | 0 | -153.72M | -103.81M | -2.00 |
Alector Inc Stock (ALEC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Downgrade | Mizuho | Outperform → Neutral |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-04-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-29-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-26-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-14-23 | Upgrade | Stifel | Hold → Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Sep-25-23 | Initiated | Goldman | Sell |
| Sep-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-13-22 | Initiated | Goldman | Sell |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Sep-27-21 | Initiated | William Blair | Outperform |
| Jan-15-21 | Resumed | BofA Securities | Buy |
| Jun-24-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Goldman | Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-19-20 | Initiated | Stifel | Buy |
| Nov-21-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | Barclays | Overweight |
| Mar-04-19 | Initiated | BofA/Merrill | Buy |
| Mar-04-19 | Initiated | Morgan Stanley | Overweight |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
View All
Alector Inc Stock (ALEC) Latest News
Dimensional Fund Advisors LP Raises Position in Alector, Inc. (NASDAQ:ALEC) - Defense World
Alector at BofA Securities 2025 Healthcare Conference: Strategic Innovations in Brain Disorder Therapies - Investing.com
Alector Reports Increased Loss, Advances Clinical Pipeline - TipRanks
Alector stock price target raised to $10 at H.C. Wainwright By Investing.com - Investing.com Nigeria
Alector stock price target raised to $10 at H.C. Wainwright - Investing.com
Alector, Inc. (NASDAQ:ALEC) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.26 - Yahoo Finance
US$5.26That's What Analysts Think Alector, Inc. (NASDAQ:ALEC) Is Worth After These Results - simplywall.st
Alector (ALEC) Maintains Buy Rating as Price Target Increases | - GuruFocus
Alector First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Alector (ALEC) Price Target Raised by H.C. Wainwright | ALEC Sto - GuruFocus
Alector (ALEC) Maintains Buy Rating as Price Target Increases | ALEC Stock News - GuruFocus
Alector (ALEC) Price Target Raised by H.C. Wainwright | ALEC Stock News - GuruFocus
Alector Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Alector Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Alector (ALEC) Reports Q1 Revenue Shortfall, Advances Drug Trials | ALEC Stock News - GuruFocus
Alector reports Q1 EPS (41c), consensus (46c) - TipRanks
Alector Inc Reports Q1 2025 Earnings: EPS Loss of $0.41 Beats Estimates, Revenue Falls Short at $3.7 Million - GuruFocus
Alector, Inc. SEC 10-Q Report - TradingView
Alector to Participate in Upcoming Healthcare Conferences - GlobeNewswire
Alector Sets Stage for Major Healthcare Conference Appearances: BofA and H.C. Wainwright Presentations Coming Up - Stock Titan
Alector, Inc. (NASDAQ:ALEC) Position Raised by Invesco Ltd. - Defense World
Alector Inc (NASDAQ: ALEC) Analysts Expect It Could Climb 71.8% From Current Levels. - Stocksregister
Alector, Inc. (NASDAQ:ALEC) Stock Catapults 27% Though Its Price And Business Still Lag The Industry - simplywall.st
Alector Inc (ALEC) shows promising results - uspostnews.com
Alector Inc [ALEC] Shares Fall Approximately -76.81% Over the Year - knoxdaily.com
Market Highlights: Alector Inc (ALEC) Ends on a High Note at 1.22 - DWinneX
Alector Inc (ALEC) Stock: A Comprehensive 52-Week Review - investchronicle.com
XTX Topco Ltd Acquires 22,381 Shares of Alector, Inc. (NASDAQ:ALEC) - Defense World
Geode Capital Management LLC Boosts Stake in Alector, Inc. (NASDAQ:ALEC) - Defense World
Brokerages Set Alector, Inc. (NASDAQ:ALEC) Price Target at $3.50 - Defense World
Alector Inc (ALEC): A Sitting Duck With -250.88% Upside Potential - Stocksregister
Following a 75% decline over last year, recent gains may please Alector, Inc. (NASDAQ:ALEC) institutional owners - simplywall.st
There is no way Alector Inc (ALEC) can keep these numbers up - Sete News
A Guide To The Risks Of Investing In Alector Inc (ALEC) - knoxdaily.com
ALEC’s Stock Market Puzzle: Piecing Together 2023’s Performance - investchronicle.com
Neogenomics Inc (NEO) Stock’s Detailed Analysis - Marketing Sentinel
Alector Inc (ALEC): What Makes The Stock Good? - Marketing Sentinel
Gentherm Inc Is A Buy Small Cap Stock: Analysts - Marketing Sentinel
Alector, Inc. (NASDAQ:ALEC) Holdings Cut by JPMorgan Chase & Co. - Defense World
Alector concludes enrolment in Phase II trial of Alzheimer’s treatment - Yahoo Finance
What Analysts Were Expecting After Alector Inc (NASDAQ: ALEC) fell -5.95% - Stocksregister
Alector Completes Enrollment for Phase 2 Alzheimer's Trial of AL101 - marketscreener.com
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease - GlobeNewswire
Alector (ALEC) Completes Enrollment for Alzheimer's Drug Trial | - GuruFocus
Major Milestone: Alector's Innovative Alzheimer's Drug Trial Hits Full Enrollment Ahead of Schedule - Stock Titan
Alector stock hits 52-week low at $0.99 amid sharp decline By Investing.com - Investing.com South Africa
Alector stock hits 52-week low at $0.99 amid sharp decline - Investing.com India
Alector, Inc. (NASDAQ:ALEC) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Finance Watch: As Stocks Tumble, Offerings Slow, Financial Alternatives Rise - insights.citeline.com
Frontotemporal Dementia Pipeline 2025: Key Companies, MOA, - openPR.com
Alector stock hits 52-week low at $1.24 amid market challenges - Investing.com
Alector Inc Stock (ALEC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.17%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):